Healthcare stocks are lower, with the NYSE Healthcare Sector
Index retreating about 0.4% and shares of healthcare companies in
the S&P 500 down 0.2% as a group.
In company news, ThermoGenesis (
) is down more than 8% at $7.51 a share after late Thursday
reporting a Q4 loss of $0.14 per share, $0.10 wider than its net
loss during the same quarter last year.
Revenue for the medical device manufacturer declined 8.9% year
over year to $4.1 million. No analyst estimates were available for
KOOL has eight autologous cell therapies in various stages of
clinical development, targeting osteoarthritis, avascular necrosis
and critical limb ischemia among other medical issues. Last month,
it announced plans to acquire TotipotentRX, with the combined
companies to be known as Cesca Therapeutics with a focus on
In other sector news,
(-) APRI, (-1.5%) Swiss regulators recommend against allowing
for sales of the company's Vitaros topical treatment for erectile
dysfunction, based on certain quality related issues. APRI plans to
submit an appeal within 30 days.
(-) AKRX, (1.6%) Bank of America raises price target by $3 to
$21 a share while reiterating its Buy rating for the generic
drug-maker, which earlier this week announced a $640-mln buyout bid
for Hi-Tech Pharmacal (
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.